Point of Care (PoC) Molecular Diagnostics Market Size By Technology (PCR, In Situ Hybridization, Sequencing, Isothermal Amplification), By Application (Infectious Disease, {Flu, Respiratory Syncytial Virus (RSV), Tuberculosis (TB), HIV, Gonorrhea, Chlamydia, Hepatitis C, Hepatitis B}, Oncology, Hematology), By End-use (Hospitals, Clinics), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026
Published Date: Sep 2020 | Report ID: GMI2210 | Authors: Sumant Ugalmugle, Rupali Swain
Industry Trends
Point of Care Molecular Diagnostics Market size valued at USD 1.6 billion in 2019 and is expected to witness 8% CAGR from 2020 to 2026. Surging prevalence of chronic illness such as cancer and infectious diseases will drive the market growth.
Rising focus of key market leaders on adopting inorganic and organic growth strategies for development and expansion of PoC molecular diagnostics product portfolio will foster the market revenue. Point of care molecular diagnostics tests have rapid turnaround time, reduces the patient visits, and enable timely treatment. Advances in nanotechnology, microfluids, miniaturization will enhance the performance of point of care molecular diagnostics devices rendering significant influence on the market demand.
Get more details on this report - Request Free Sample PDF
Increasing awareness regarding early disease diagnosis for better management of infections will have a positive impact on the point of care molecular diagnostics market size. Several initiatives undertaken by government in underdeveloped and developing regions to create awareness about infectious diseases and prevention will propel the market growth. In South Africa, NHLS (National Health Laboratory Service) is a major provider of laboratory diagnostics services having a national network of around 265 pathology laboratories. The Chinese government has prioritized TB, HIV, hepatitis B, and schistosomiasis as top infectious disease priorities in the country. Foundation for Innovative New Diagnostics (FIND) is working to create awareness regarding early diagnosis and management augmenting the market progression.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2019: | USD 1.6 Billion |
| Historical Data for: | 2015 to 2019 | Forecast Period: | 2020 to 2026 |
| Forecast Period 2020 to 2026 CAGR: | 8.0% | 2026 Value Projection: | USD 2.8 Billion |
| Pages: | 140 | Tables, Charts & Figures: | 163 |
| Geographies covered (26): | U.S., Canada, Germany, UK, France, Italy, Spain, Russia, Japan, China, India, South Korea, Malaysia, Thailand, Vietnam, Philippines, Australia, Brazil, Mexico, Argentina, South Africa, Nigeria, Egypt, Morocco, Saudi Arabia, UAE | ||
| Segments covered: | Technology, Application, End-use and Region | ||
| Companies covered (10): | Abaxis Inc., Abbott Laboratories, BioMérieux SA, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, Sysmex Corporation, VIRCELL S.L, Mesa Biotech | ||
| Growth Drivers: |
|
||
| Pitfalls & Challenges: |
|
||
Get more details on this report - Request Free Sample PDF
Emergence of innovative isothermal amplification methods will boost the industry growth
The isothermal amplification technology segment is estimated to witness around 9% growth rate during the forecast period. Increasing adoption of novel methods in isothermal amplification such as loop-mediated isothermal amplification (LAMP) impels the market demand. LAMP technology is among the widely used methods as it has several benefits including ease of use, rapid, and low cost set up.
Surging prevalence of infectious diseases globally will create a huge demand for PoC molecular diagnostics testing
Get more details on this report - Request Free Sample PDF
Infectious disease segment captured over 47% point of care molecular diagnostics market share in 2019. Rising incidence of infectious diseases will stimulate the demand for point of care molecular diagnostic equipment to identify causative agents and further control the spread of disease.
Similarly, surging prevalence of HIV globally will stimulate the segment growth. For instance, according to Department of Health & Human Services about 38 million people were affected with HIV/AIDS in 2019. Also, majority of people suffering from HIV are in low- and middle-income countries creating a need for point of care molecular diagnostics devices for remote locations. Thus, rising need of early diagnosis and rapid commencement for the treatment and control of infectious diseases will foster the market value.
Increasing preference towards clinics will provide lucrative market growth opportunities
The clinics end-use segment is anticipated to expand at over 8.5% CAGR through 2026. Access to less expensive and portable point of care molecular diagnostics systems that assist in timely and accurate patient diagnostics in low resource areas will surge its adoption rate in clinics. Furthermore, clinics provide convenient access to quality care, manage healthcare spending as well as improves productivity.
Favorable government initiatives in European region will fuel the market expansion
Get more details on this report - Request Free Sample PDF
Europe’s point of care molecular diagnostics market size crossed USD 470 million in 2019 due to increasing availability and usage of PoC molecular diagnostics testing in the region. Increasing geriatric population base prone to variety of infectious diseases and surging life expectancy will propel the need for early diagnostics. Also, government is conducting several programs and campaigns to create awareness level among people regarding several infectious diseases.
Strategic initiatives adopted by key companies have enabled to strengthen their market position
Some of the leading players operating in the market include Abbott Laboratories, Bio-Rad Laboratories, Danaher, Sysmex, Vircell and Roche. The industry participants have adopted several strategic initiatives such as acquisitions, new product launches, that have provided financial stability and helped them to evolve as major market players.
Recent Industry Developments:
- In April 2020, Siemens received FDA clearance for RapidPoint 500e blood gas analyzer. This strategy helps the company in strengthening its point of care molecular diagnostics product portfolio.
- In January 2020, Hitado GmbH, a subsidiary of Sysmex Corporation signed distribution agreement with SphingoTec GmbH for commercialization of Nexus IB10 platform. This strategy was envisioned to enhance its distribution network, thereby securing its industry position in point of care molecular diagnostics.
The point of care molecular diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2015 to 2026, for the following segments:
Market, By Technology
- PCR
- In situ hybridization
- Sequencing
- Isothermal amplification
- Others
Market, By Application
- Infectious disease
- Flu
- Respiratory syncytial virus (RSV)
- Tuberculosis (TB)
- Gonorrhea
- Chlamydia
- Hepatitis B
- Hepatitis C
- HIV
- Others
- Oncology
- Hematology
- Others
Market, By End-use
- Hospitals
- Clinics
- Others
The above information is provided for the following regions and countries:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Asia Pacific
- Japan
- China
- India
- South Korea
- Malaysia
- Thailand
- Vietnam
- Philippines
- Australia
- Latin America
- Brazil
- Argentina
- Mexico
- Middle East & Africa
- South Africa
- Nigeria
- Egypt
- Morocco
- Saudi Arabia
- UAE
Frequently Asked Questions (FAQ) :
Buy Now
Need a Discount? Get in touch with us for special pricing
Request DiscountConnect with our sales team
- Phone: 1-302-846-7766
- Toll Free: 1-888-689-0688
- Email: sales@gminsights.com
- Chat With Us: Click here to start
Premium Report Details
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Customer Service
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.
GMIPulse, our report store
We have introduced ‘GMIPulse’, which is our report store; designed to offer clients a one-stop platform for all market research and business intelligence requirements. Clients can access reports, presentations, raw data excel sheets as well as detailed company profiles. GMIPulse allows you to track relevant industries and stay informed with latest innovation, competitive and regulatory developments to help design strategic framework.